Therapeutic Nonsense Suppression Modalities: From Small Molecules to Nucleic Acid-Based Approaches

Area of Science:

• Genetics
• Molecular Biology
• Biochemistry

Background:

• Nonsense mutations introduce premature termination codons (PTCs), yielding truncated, non-functional proteins.
• These mutations are implicated in numerous genetic disorders, including cystic fibrosis, Duchenne muscular dystrophy, and various cancers.
• Nonsense-mediated mRNA decay (NMD) is a cellular mechanism that degrades PTC-containing mRNA, potentially limiting disease severity.

Purpose of the Study:

• To provide an updated review of state-of-the-art nonsense suppression technologies.
• To focus on novel therapeutic modalities for treating diseases caused by nonsense mutations.
• To discuss the advantages and disadvantages of various emerging treatment strategies.

Main Methods:

• Review of recent advancements in nonsense suppression strategies.
• Analysis of therapeutic modalities including small molecules, antisense oligonucleotides, tRNA suppressors, ADAR-mediated RNA editing, targeted pseudouridylation, and gene/base editing.
• Discussion of the mechanisms, potential, and challenges associated with each modality.

Main Results:

• Significant progress has been made in developing new approaches for nonsense suppression.
• Novel strategies include promoting translational readthrough of PTCs and inhibiting the NMD pathway.
• Emerging modalities show therapeutic potential but also present challenges in manufacturing and off-target effects.

Conclusions:

• Nonsense suppression technologies are rapidly advancing, offering new therapeutic avenues for genetic diseases.
• Each modality, from small molecules to gene editing, has unique benefits and drawbacks.
• Continued research is crucial to overcome limitations and translate these promising technologies into effective clinical treatments.